PHAT
Phathom Pharmaceuticals, Inc.
$11.05
+0.01
(+0.05%)
Mkt Cap
876.61M
Volume
113,601
52W Range
7.61-18.31
Sector
Healthcare
Beta
0.49
EPS (TTM)
-2.12
P/E Ratio
-5.48
Revenue (TTM)
204.89M
Rev Growth (5Y)
N/A
EPS Growth (5Y)
N/A
Company Description
Phathom Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, dedicated to advancing and commercializing therapies for gastrointestinal ailments. A pivotal asset for the company is vonoprazan, a distinctive potassium-competitive acid blocker (P-CAB) designed to effectively inhibit gastric acid production, for which Phathom holds commercial rights across the United States, Europe, and Canada. This compound is currently undergoing advanced (Phase III) clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD), and also as a component of combination therapy with antibiotics to combat Helicobacter pylori (H. pylori) infection. Established in 2018, Phathom Pharmaceuticals maintains its corporate headquarters in Florham Park, New Jersey.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 175.11M | 55.25M | 682,000 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (221.25M) | (334.33M) | (201.59M) | (197.72M) | (143.88M) | (129.07M) | (209.74M) | (1.29M) |
| EPS | -3.03 | -5.29 | -3.93 | -5.70 | -4.00 | -4.01 | -8.48 | -0.15 |
| Free Cash Flow | (166.78M) | (266.90M) | (139.21M) | (147.57M) | (148.78M) | (70.73M) | (61.76M) | (1.02M) |
| FCF / Share | -2.29 | -4.22 | -2.71 | -3.77 | -4.02 | -2.13 | -2.50 | -0.12 |
| Operating CF | (166.78M) | (266.77M) | (137.58M) | (146.53M) | (148.46M) | (69.69M) | (36.51M) | (1.02M) |
| Total Assets | 259.15M | 378.32M | 413.84M | 164.81M | 189.43M | 295.11M | 257.18M | 902,000 |
| Total Debt | 211.80M | 554.95M | 139.03M | 97.07M | 91.34M | 49.02M | 23.57M | 1.95M |
| Cash & Equiv | 129.97M | 297.26M | 381.39M | 155.38M | 183.26M | 287.50M | 243.76M | 879,000 |
| Book Value | (438.17M) | (253.58M) | (72.76M) | (74.81M) | 72.16M | 194.27M | 227.96M | (1.29M) |
| Return on Equity | N/A | N/A | N/A | N/A | -1.99 | -0.66 | -0.92 | N/A |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 58.30M | 57.58M | 49.50M | 39.50M | 28.52M | 29.66M | 16.35M | 7.32M | 1.91M | 682,000 | 0 | 0 |
| Net Income | (30.37M) | (21.15M) | (29.97M) | (75.81M) | (94.32M) | (74.45M) | (85.58M) | (91.45M) | (82.85M) | (79.57M) | (43.24M) | (40.97M) |
| EPS | -0.37 | -0.29 | -0.41 | -1.05 | -1.31 | -1.05 | -1.32 | -1.56 | -1.42 | -1.39 | -0.76 | -0.84 |
| Free Cash Flow | (15.65M) | (4.89M) | (14.14M) | (62.73M) | (84.95M) | (63.46M) | (63.49M) | (70.77M) | (69.06M) | (44.27M) | (32.85M) | (22.21M) |
| FCF / Share | -0.19 | -0.07 | -0.19 | -0.87 | -1.18 | -0.89 | -0.98 | -1.21 | -1.18 | -0.77 | -0.58 | -0.46 |
| Operating CF | (15.65M) | (5.00M) | (14.12M) | (62.73M) | (84.93M) | (63.46M) | (63.57M) | (70.72M) | (69.02M) | (43.80M) | (31.91M) | (22.20M) |
| Total Assets | 305.12M | 259.15M | 240.29M | 250.22M | 294.21M | 378.47M | 387.04M | 319.38M | 356.50M | 413.84M | 236.99M | 265.04M |
| Total Debt | 166.30M | 211.80M | 209.81M | 574.50M | 564.64M | 554.95M | 518.99M | 506.38M | 469.05M | 139.03M | 226.40M | 219.39M |
| Cash & Equiv | 180.90M | 129.97M | 135.16M | 149.57M | 212.31M | 297.26M | 334.68M | 276.24M | 322.23M | 381.39M | 213.68M | 248.85M |
| Book Value | (336.95M) | (438.17M) | (422.53M) | (405.83M) | (338.38M) | (253.58M) | (187.11M) | (233.83M) | (148.50M) | (72.76M) | (17.77M) | 17.60M |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -2.33 |
PHAT News
Phathom Pharmaceuticals Completes Patient Enrollment Ahead of Schedule in Phase 2 pHalcon-EoE-201 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE)
Phathom Pharmaceuticals, Inc. (PHAT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
Phathom Pharmaceuticals Highlights Breadth of Independent Vonoprazan Research at Digestive Disease Week 2026 Annual Meeting
Phathom Pharmaceuticals to Highlight VOQUEZNA® (vonoprazan) at DDW 2026 Annual Meeting
Phathom Pharmaceuticals, Inc. (PHAT) Q1 2026 Earnings Call Transcript
Phathom Pharmaceuticals, Inc. (PHAT) Reports Q1 Loss, Tops Revenue Estimates
Phathom Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update
Phathom Pharmaceuticals to Report First Quarter 2026 Financial Results and Provide Business Update on Thursday, April 30, 2026
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Receives Consensus Rating of “Moderate Buy” from Analysts